Viatris Q2 FY25: where the revenue came from and where it went
The income statement of Viatris for this quarter, down to the operating result, as one diagram: what earned the revenue and what it went on. The bottom line is withheld; the note under the table says why.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 7, 2025
Revenue$3.58B
−6% year over year
Gross profit$1.33B
37% margin
Operating profit$0.23B
7% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.58 | 100% | −6% |
| Brands | 2.29 | 64% | |
| Lipitor | 0.39 | 11% | |
| Other | 0.29 | 8% | |
| Norvasc | 0.18 | 5% | |
| Epi pen auto injectors | 0.14 | 4% | |
| Lyrica | 0.13 | 3% | |
| Viagra | 0.10 | 3% | |
| Celebrex | 0.07 | 2% | |
| Cost of revenue | −2.25 | 63% | |
| Gross profit | 1.33 | 37% margin | −1pp |
| R&D | −0.22 | 6% | +1pp |
| SG&A | −0.88 | 25% | −1pp |
| Operating profit | 0.23 | 7% margin | +13pp |
95 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest